Futura Medical Share News (FUM)

Drug developer Syntopix shares rallied as it reported positive phase 2 results for its lead dermatological compound SYN0126, for the treatment of acneic skin. Following the results, Syntopix has decided to focus its development efforts around three specific core compounds: SYN0126, SYN1113 and SYN0017, in order to accelerate commercialisation. Syntopix has also renewed its exclusivity and evaluation agreement with another 'major consumer healthcare company' announced on 14 April 2009.The potential of the Stockton mine and introduction of a new mine plan have had the desired effect with the mine becoming cash flow positive from its operations, Atlantic Coal reports.Revenues of circa $4m were achieved from sales of 32,348 tons for the four months to October, compared to revenues of circa $3.4m from 27,223 tons sold during the 6 months to June 2009. The company has stock piles on site as at 31 October 2009 of 71,386 ROM tons and 6,365 tons of Clean Coal. This will be sold in the coming months and will have a positive impact on revenues going forward.Xstrata's copper arm in Chile has selected Brady's Aquarius solution to supply the organisation's metal trading business in that country.Recruiter Higham returned a profits £40,000 against a loss of £261,000 in the half year to September, despite revenue dipping to £3.77m (2008: £5.66m). The current business has been stabilised and there are signs of recovery showing in our niche areas, it added.Pharmaceutical Group Futura has announced a placing worth £1.46m to support the regulatory approval of its 'erectogenic' condom the CSD500, and to provide the company with additional working capital and funds for development projects.